paclitaxel and pik 75
paclitaxel has been researched along with pik 75 in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Hayakawa, M; Kaizawa, H; Kawaguchi, K; Koizumi, T; Ohishi, T; Ohta, M; Okada, M; Parker, P; Raynaud, FI; Tsukamoto, S; Waterfield, MD; Workman, P; Yamano, M | 1 |
| Akhmedov, A; Beer, JH; Camici, GG; Eickner, T; Holy, EW; Jakob, P; Lüscher, TF; Schmitz, KP; Sternberg, K; Tanner, FC | 1 |
Other Studies
2 other study(ies) available for paclitaxel and pik 75
| Article | Year |
|---|---|
Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Humans; Hydrazones; Imidazoles; Inhibitory Concentration 50; Isoenzymes; Mice; Molecular Structure; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Subunits; Pyridines; Structure-Activity Relationship; Sulfur; Temperature; Xenograft Model Antitumor Assays | 2007 |
PI3K/p110α inhibition selectively interferes with arterial thrombosis and neointima formation, but not re-endothelialization: potential implications for drug-eluting stent design.
Topics: Animals; Cell Proliferation; Cells, Cultured; Chemotaxis; Drug-Eluting Stents; Endothelium, Vascular; GTP Phosphohydrolases; Hydrazones; Immunosuppressive Agents; Leukocytes, Mononuclear; Male; Mice, Inbred C57BL; Muscle, Smooth, Vascular; Neointima; NF-kappaB-Inducing Kinase; Nitric Oxide; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Plasminogen Activator Inhibitor 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; RNA Interference; RNA, Small Interfering; Sirolimus; Sulfonamides; Thrombosis; Tumor Necrosis Factor-alpha | 2014 |